SUBLOCADE Adherence Linked to 42% Lower Healthcare Costs in New Study
INDV has more than doubled off its 52-week low of $8.64.
Summary
Indivior Pharmaceuticals announced findings from a new real-world study demonstrating that adherence to its monthly injectable buprenorphine, SUBLOCADE, is associated with significantly lower healthcare utilization and medical costs for patients with opioid use disorder. The study, published in Frontiers in Public Health, found that SUBLOCADE-adherent patients experienced $15,017 (42%) lower annual non-MOUD medical costs per patient compared to those adherent to other medications for OUD. This positive data reinforces the economic value proposition of SUBLOCADE, potentially enhancing its market position, driving increased adoption, and supporting favorable payer coverage decisions. This news follows the company's recent strong Q4 and full-year 2025 financial results and robust 2026 guidance, further solidifying its product portfolio.
At the time of this announcement, INDV was trading at $33.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $8.64 to $38.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.